Shionogi And GSK Anti-HIV Agent Matches Merck Isentress In Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
Shionogi said its once-daily anti-HIV drug dulutegravir developed jointly with GlaxoSmithKline PLC has been proved as effective as Merck & Co’s twice-daily best-selling Isentress (raltegravir) in a Phase III trial.